South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark.
Remsima SC is a subcutaneous (SC) formulation of the autoimmune disease treatment Remsima, containing the ingredient infliximab.
It obtained a new drug approval from the US Food and Drug Administration (FDA) and a biobetter from European Medicine Agency (EMA).
The company started to supply Remsima SC to the Norwegian market in February.
The Danish government created a national tender specifically for the SC form of infliximab and Celltrion secured this tender as the sole supplier, facing no competition.
Remsima SC will be distributed directly by Celltrion's Danish subsidiary, with the initial sales phase planned to last one year starting this month.
In anticipation of growing demand, the subsidiary is ramping up its marketing efforts to increase prescription rates.
The company plans to expand its local workforce by the end of the year, enhancing its direct sales capabilities and strengthening its foothold in the European market.